The DOI matches its Crossref record; 41 of the 43 references it cites were found in a registry or an index.
Activity of P-Glycoprotein, a β-Amyloid Transporter at the Blood–Brain Barrier, Is Compromised in Patients with Mild Alzheimer Disease
Open accessAbstract
UNLABELLED: Studies in animals and postmortem human brain tissue support a role for P-glycoprotein in clearance of cerebral β-amyloid across the blood-brain barrier (BBB). We tested the hypothesis that BBB P-glycoprotein activity is diminished in Alzheimer disease (AD) by accounting for an AD-related reduction in regional cerebral blood flow (rCBF). METHODS: We compared P-glycoprotein activity in mild-AD patients (n = 9) and cognitively normal, age-matched controls (n = 9) using PET with a labeled P-glycoprotein substrate, (11)C-verapamil, and (15)O-water to measure rCBF. BBB P-glycoprotein activity was expressed as the (11)C-verapamil radioactivity extraction ratio ((11)C-verapamil brain distributional clearance, K1/rCBF). RESULTS: Compared with controls, BBB P-glycoprotein activity was significantly lower in the parietotemporal, frontal, and posterior cingulate cortices and hippocampus of mild AD subjects. CONCLUSION: BBB P-glycoprotein activity in brain regions affected by AD is reduced and is independent of rCBF. This study improves on prior work by eliminating the confounding effect that reduced rCBF has on assessment of BBB P-glycoprotein activity and suggests that impaired P-glycoprotein activity may contribute to cerebral β-amyloid accumulation in AD. P-glycoprotein induction or activation to increase cerebral β-amyloid clearance could constitute a novel preventive or therapeutic strategy for AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Studies using [ 11 C]verapamil, an ABCB1 (P-gp) ligand and PET, have shown increased uptake of verapamil in certain brain regions in individuals with early AD, suggesting diminished ABCB1-mediated active efflux of xenobiotics and drugs at the BBB (33, 142), and possibly faulty A 𝛃 BBB clearance based on experimental studies (115, 400, 632).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [142]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tzourio-Mazoyer, N., Landeau, B., Papathanassiou, D., Crivello, F., Etard, O., Delcroix, N., Mazoyer, B., & Joliot, M. (2002) · NeuroImage · doi:10.1006/nimg.2001.0978 · Cited by 16,319
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Nonparametric permutation tests for functional neuroimaging: A primer with examples
Nichols, T. E., & Holmes, A. P. (2002) · Human Brain Mapping · doi:10.1002/hbm.1058 · Cited by 6,256
Querfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569
Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078
Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease
Minoshima, S., Giordani, B., Berent, S., Frey, K. A., Foster, N. L., & Kuhl, D. E. (1997) · Annals of Neurology · doi:10.1002/ana.410420114 · Cited by 1,802
Self-citation(1995) · PubMed Central · doi:10.2967/jnumed.120.252510a · Cited by 996
Self-citationBrain glucose metabolism in the early and specific diagnosis of Alzheimer?s disease
Mosconi, L. (2005) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-005-1762-7 · Cited by 938
The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin
Greiner, B., Eichelbaum, M. F., Fritz, P., Kreichgauer, H. P., von Richter, O., Zundler, J., & Kroemer, H. K. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6663 · Cited by 917
Neurovascular mechanisms of Alzheimer's neurodegeneration
Zlokovic, B. V. (2005) · Trends in Neurosciences · doi:10.1016/j.tins.2005.02.001 · Cited by 770
Cirrito, J. R. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25247 · Cited by 660
Vogelgesang, S., Cascorbi, I., Schroeder, E., Pahnke, J., Kroemer, H. K., Siegmund, W., Kunert‐Keil, C., Walker, L. C., & Warzok, R. (2002) · Pharmacogenetics · doi:10.1097/00008571-200210000-00005 · Cited by 357
Hartz, A. M. S., Miller, D. S., & Bauer, B. (2010) · Molecular Pharmacology · doi:10.1124/mol.109.061754 · Cited by 329
Blood–brain barrier P-glycoprotein function in Alzheimer's disease
van Assema, D. M. E., Lubberink, M., Bauer, M., van der Flier, W. M., Schuit, R. C., Windhorst, A. D., Comans, E. F. I., Hoetjes, N. J., Tolboom, N., Langer, O., et al. (2012) · Brain · doi:10.1093/brain/awr298 · Cited by 318
Sasongko, L., Link, J., Muzi, M., Mankoff, D. A., Yang, X. N., Collier, A. C., Shoner, S., & Unadkat, J. D. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.01.022 · Cited by 271
Self-citationMinoshima, S., Frey, K. A., Foster, N. L., & Kuhl, D. E. (1995) · Journal of Computer Assisted Tomography · doi:10.1097/00004728-199507000-00006 · Cited by 252
Self-citationThe nature and effects of cortical microvascular pathology in aging and Alzheimer's disease
Bailey, T. L., Rivara, C. B., Rocher, A. B., & Hof, P. R. (2004) · Neurological Research · doi:10.1179/016164104225016272 · Cited by 213
Blood–brain barrier permeability in Alzheimer's disease: a case–control MRI study
Starr, J. M., Farrall, A., Armitage, P. A., McGurn, B., & Wardlaw, J. M. (2009) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2008.04.003 · Cited by 201
Alzheimer's disease is a vasocognopathy: a new term to describe its nature
de la Torre, J. C. (2004) · Neurological Research · doi:10.1179/016164104225016254 · Cited by 168
Decreased medial temporal oxygen metabolism in Alzheimer's disease shown by PET.
Ishii, K., Kitagaki, H., Kono, M., & Mori, E. (1996) · PubMed · Cited by 159
Clinical history, brain metabolism, and neuropsychological function in Alzheimer's disease
Cutler, N. R., Haxby, J. V., Duara, R., Grady, C. L., Kay, A. D., KESSLER, R. M., Sundaram, M., & Rapoport, S. I. (1985) · Annals of Neurology · doi:10.1002/ana.410180305 · Cited by 153
Quantitative assessment of cerebral blood flow in patients with Alzheimer's disease by SPECT.
Bartenstein, P., Minoshima, S., Hirsch, C., Buch, K., Willoch, F., Mösch, D., Schad, D., Schwaiger, M., & Kurz, A. (1997) · PubMed · Cited by 143
Self-citationABC efflux transporters in brain vasculature of Alzheimer's subjects
Wijesuriya, H. C., Bullock, J. Y., Faull, R. L. M., Hladky, S. B., & Barrand, M. A. (2010) · Brain Research · doi:10.1016/j.brainres.2010.08.034 · Cited by 141
Muzi, M., Mankoff, D. A., Link, J. M., Shoner, S., Collier, A. C., Sasongko, L., & Unadkat, J. D. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.059162 · Cited by 132
Self-citationSchwarz, U. I., Hanso, H., Oertel, R., Miehlke, S., Kuhlisch, E., Glaeser, H., Hitzl, M., Dresser, G. K., Kim, R. B., & Kirch, W. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100191 · Cited by 129
Positron emission tomography in patients with clinically diagnosed Alzheimer's disease.
McGeer, P. L., Kamo, H., Harrop, R., Li, D. K., Tuokko, H. A., McGeer, E. G., Adam, M. J., Ammann, W., Beattie, B. L., & Calne, D. B. (1986) · Europe PMC (PubMed Central) · Cited by 111
Ishii, K., Sasaki, M., Yamaji, S., Sakamoto, S., Kitagaki, H., & Mori, E. (1997) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/bf00841407 · Cited by 94
Abnormalities of Energy Metabolism in Alzheimer's Disease Studied with PETa
Heiss, W., Szelies, B., KESSLER, J., & Herholz, K. (1991) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1991.tb00192.x · Cited by 93
Lubberink, M., Luurtsema, G., van Berckel, B. N. M., Boellaard, R., Toornvliet, R., Windhorst, A. D., Franssen, E. J. F., & Lammertsma, A. A. (2006) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600349 · Cited by 90
Lazarova, N., Zoghbi, S. S., Hong, J. S., Seneca, N. M., Tuan, E., Gladding, R. L., Liow, J., Taku, A., Innis, R. B., & Pike, V. W. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800510m · Cited by 85
Treating Alzheimer’s disease with monoclonal antibodies: current status and outlook for the future
Prins, N. D., & Scheltens, P. (2013) · Alzheimer s Research & Therapy · doi:10.1186/alzrt220 · Cited by 79
Eyal, S., Ke, B., Muzi, M., Link, J. M., Mankoff, D. A., Collier, A. C., & Unadkat, J. D. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.11 · Cited by 67
Self-citationBeta amyloid effects on expression of multidrug efflux transporters in brain endothelial cells.
Kania, K., Wijesuriya, H. C., Hladky, S., & Barrand, M. (2011) · Brain Research · doi:10.1016/j.brainres.2011.08.044 · Cited by 63
Cerebral metabolic and cognitive studies in dementia with frontal lobe behavioral features
Kumar, A. A., Schapiro, M. B., Haxby, J. V., Grady, C. L., & Friedland, R. P. (1990) · Journal of Psychiatric Research · doi:10.1016/0022-3956(90)90050-z · Cited by 54
Chung, F., Eyal, S., Muzi, M., Link, J. M., Mankoff, D. A., Kaddoumi, A., O’Sullivan, F., Hsiao, P., & Unadkat, J. D. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00538.x · Cited by 37
Self-citationKe, A. B., Eyal, S., Chung, F., Link, J. M., Mankoff, D. A., Muzi, M., & Unadkat, J. D. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.111732 · Cited by 28
Self-citationSchwartz, J. B., Capili, H., & Wainer, I. W. (1994) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1994.151 · Cited by 27
Disease Modifying Drugs Targeting β-Amyloid
Ozudogru, S. N., & Lippa, C. F. (2012) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317512452034 · Cited by 26
O’Sullivan, F., Kirrane, J., Muzi, M., O'Sullivan, J. N., Spence, A. M., Mankoff, D. A., & Krohn, K. A. (2009) · IEEE Transactions on Medical Imaging · doi:10.1109/tmi.2009.2029096 · Cited by 20
Self-citationDuran, F., Zampieri, F. G., Bottino, C. C. M., Buchpiguel, C. A., & Busatto, G. F. (2007) · Clinics · doi:10.1590/s1807-59322007000400002 · Cited by 17
Cited by
Sorted by citations
Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders
Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.188 · Cited by 3,076
Blood-Brain Barrier: From Physiology to Disease and Back
Sweeney, M. D., Zhao, Z., Montagne, A., Nelson, A. R., & Zlokovic, B. V. (2019) · Physiological Reviews · doi:10.1152/physrev.00050.2017 · Cited by 2,312
The role of brain vasculature in neurodegenerative disorders
Sweeney, M. D., Kisler, K., Montagne, A., Toga, A. W., & Zlokovic, B. V. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0234-x · Cited by 998
Alzheimer’s disease: A matter of blood–brain barrier dysfunction?
Montagne, A., Zhao, Z., & Zlokovic, B. V. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20171406 · Cited by 672
Impact of Metabolic Syndrome on Neuroinflammation and the Blood–Brain Barrier
Dyken, P. C. V., & Lacoste, B. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00930 · Cited by 377
Metadata
- Authors
- Deo, A. K., Borson, S., Link, J. M., Domino, K., Eary, J. F., Ke, B., Richards, T. L., Mankoff, D. A., Minoshima, S., O’Sullivan, F., Eyal, S., Hsiao, P., Maravilla, K., & Unadkat, J. D.
- Affiliations
- University of Washington (US)
- ORCID
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2014-05-19
- Volume
- 55
- Issue
- 7
- Pages
- 1106-1111
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- PMC
- PMC4691246
- OpenAlex
- W2130945756
- Cited by
- 193
- References
- 43
- Citations by year
- 2026: 8 · 2025: 14 · 2024: 8 · 2023: 28 · 2022: 17 · 2021: 16 · 2020: 25 · 2019: 16 · 2018: 17 · 2017: 17 · 2016: 13 · 2015: 10 · 2014: 3
- FWCI
- 6.92
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Nuclear Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- University of Washington
- National Institutes of Health (TL1TR000422, UL1TR002319)
- National Institute on Aging (AG 031485, R33AG031485)
- National Center for Research Resources (TL1RR025016)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Keywords
- P-glycoprotein, blood-brain barrier, Alzheimer's disease, amyloid-beta clearance, regional cerebral blood flow, [11C]verapamil, amyloid PET, hippocampus, temporoparietal cortex, frontal cortex, posterior cingulate cortex
- MeSH terms
- Adult, Aged, Alzheimer Disease, Blood-Brain Barrier, Carbon Radioisotopes, Cerebrovascular Circulation, Female, Humans, Male, Middle Aged, Oxygen Radioisotopes, Verapamil, Water, Case-Control Studies, Amyloid beta-Peptides, ATP Binding Cassette Transporter, Subfamily B, Member 1, Positron-Emission Tomography, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
